Welcome to Pipeline Review

Generex Biotechnology, and their wholly owned subsidiary Antigen Express, are developing promising new drugs to treat diabetes, as well as synthetic peptide vaccines targeting HER2/neu cancer and pandemic flu. The flagship product for Generex is Oral-lyn buccal insulin. Antigen Express' leading vaccine is the AE37 HER2/neu synthetic peptide vaccine to prevent breast cancer recurrence. I am not qualified to offer investment or medical advice, and make no claims that I am an expert in these areas. I am a layman and a shareholder in this company. The left side of Pipeline Review holds blogs regarding Generex and Antigen Express, while the right side offers items of due diligence mixed with my analysis which may be of interest to others seeking to learn about Generex's pipeline. If the left side only shows the latest blog, click on the word home to view them all.

Search This Blog

Wednesday, April 25, 2012

Antigen Express' Synthetic Peptide Vaccine Technology to be Featured at ASCO 2012

New data from Antigen Express' ongoing Phase II study of the AE37 vaccine will be presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 1 - 5 June 2012. Also, an oral abstract presentation followed by a discussion will be given focusing on Antigen Express' proprietory Ii-Key hybrid technology, which has been proven to greatly enhance the potency of CD4+ T helper cells.

AE37, an immunotherapeutic synthetic peptide vaccine to prevent relapse in patients who have had breast cancer, was most recently highlighted during a press conference organized by the American Association for Cancer Research, after a presentation titled "Immune Response Assessment in a Phase II Trial of AE37 HER2 Peptide Vaccine" by Dr. Diane F Hale. A press release from the AACR regarding that presentation can be found here.

On April 25th, ASCO unveiled the eplanner for their Annual Meeting, which opened the door to finding the titles of the new presentations. Full abstracts for the Annual Meeting will be available on ASCO's website after 6 pm on May 16th. Here is what we have learned so far:

Abstract #625

An assessment of disease features and immune response in breast cancer patients that did not recur after receiving HER2 peptide, AE37 vaccine in a randomized phase II trial.

Diane F. Hale, MD, Poster Board: #12D

This poster will be presented during the "Breast Cancer - HER2/ER Sessions on June 2nd between 8:00 am and 12:00 pm in S Hall A2.

Abstract 2508

From bench to bedside: The use of the li-Key technology to improve helper peptides for clinical use in cancer vaccines

This is an oral abstract presentation being given by Timothy J Vreeland, with a discussion to folllow moderated by John Timmerman, MD. This highlighted event will be heard Monday, June 4th, during the "Developmental Therapeutics - Clinical Pharmacology and Immunotherapy" session held between 3:00 and 6:00 pm in the E Arie Crown Theater.

Be on the lookout for Generex, the parent company of Antigen Express, to provide more detailed updates as ASCO approaches.